Vogliviga GM1/0.1 Tablet in PCD pharma franchise in Hyderabad

Vogliviga GM1/0.1 Tablet in pharmaceutical manufacturing company in Mumbai

Vogliviga GM1/0.1 Tablet in diabetic pharma franchise in Pune

Vogliviga GM1/0.1 Tablet in pharma suppliers in Delhi

Vogliviga GM1/0.1 Tablet in pharma export companies in Kolkata
Vogliviga GM1/0.1 Tablet in pharma franchise opportunities in Bengaluru

Home/Products /glimepiride-1mg-voglibose-1mg-metformin-hcl-layered-tablets

Vogliviga GM1- 0.1 Tablet

Composition : Glimepiride I.P. 1mg + Voglibose I.P. 0.1mg + Metformin HCL I.P. 500mg Bi-Layered Tablets

Dosage Form : Tablet

Packaging Type : Blister

Packaging : 10*10

Price : ₹1/-

Vogliviga GM1/0.1 Tablet is a triple combination antidiabetic formulation containing Glimepiride 1mg, Voglibose 0.1mg, and Metformin HCl 500mg in a bi-layered tablet form. This formulation provides a synergistic approach to managing type 2 diabetes mellitus. Glimepiride enhances insulin secretion from pancreatic beta cells, Metformin improves insulin sensitivity and decreases hepatic glucose output, while Voglibose delays carbohydrate absorption in the intestine, thereby controlling postprandial glucose spikes. This fixed-dose combination is ideal for patients who need multi-targeted therapy for optimal glycemic control.

Read More

About the Product

Vogliviga GM1/0.1 Tablet is a triple combination antidiabetic formulation containing Glimepiride 1mg, Voglibose 0.1mg, and Metformin HCl 500mg in a bi-layered tablet form. This formulation provides a synergistic approach to managing type 2 diabetes mellitus. Glimepiride enhances insulin secretion from pancreatic beta cells, Metformin improves insulin sensitivity and decreases hepatic glucose output, while Voglibose delays carbohydrate absorption in the intestine, thereby controlling postprandial glucose spikes. This fixed-dose combination is ideal for patients who need multi-targeted therapy for optimal glycemic control.

Patients may experience gastrointestinal discomfort such as bloating, nausea, flatulence, or mild diarrhea. Hypoglycemia can occur, especially if meals are skipped. Long-term use of Metformin may lead to Vitamin B12 deficiency.

Used for the management of type 2 diabetes mellitus in patients who require combination therapy to control fasting and postprandial blood sugar levels effectively.

Not suitable for patients with type 1 diabetes, severe renal or hepatic impairment, or gastrointestinal disorders. Blood glucose levels should be monitored regularly. Avoid alcohol intake during the treatment. Always follow physician guidance for dose adjustments.

Store in a cool, dry place below 25°C. Protect from direct sunlight and moisture. Keep out of the reach of children.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Strategic Advisory

Ms. Shiwani Dhiman

VP-Strategic Outreach & Engagement

Ms. Shiwani specializes in market outreach and strategic partnership orchestration for entrepreneurs building scalable PCD Pharma Franchise models.

View Professional Profile

Start Your Journey

Partner With Cafoli

Ready to Dominate your territory with a Monopoly-Based PCD Franchise? Join our rapidly growing network of successful franchise partners and turn your ambitions into reality. Limited Territories Available — Don’t Miss Out!

Quick Navigation